Metrics raised 3
- FY27 capex plan increased from ₹125 crores to ₹250 crores for two new production buildings at Pakhajan
- FY28 revenue target raised to >₹1,600 crores (revised from prior undisclosed lower target; excludes new capex revenue)
- EBITDA margin guidance raised to sustain ~24% through FY27 (from historical guidance of 17-20%)
Event Participants
Executives
2 Chirag Shah, Parag Jhaveri
Analysts
14 Aman Thadani, Amar Maurya, Dakshesh Gupta, Disha Chamriya, Jainam Madrecha, Lovish Soien, Meet Katrodiya, Nishita Shanklesha, Parth Agarwal, Pujan Shah, Rikin Shah, Rohit Sinha, Shivam Vashi, Subhanu
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹308 crores | Highest quarterly revenue; ~60% YoY growth driven by 42% volume increase |
| Volumes | +42% YoY | Driven by approvals from key global customers in Industrial Chemicals and higher customer offtake |
| EBITDA | ₹74.42 crores | Margin expanded to 24.2% from ~17% prior, driven by improved product mix, higher utilization and operating leverage |
| PAT | ₹36 crores | PAT margin of 11.7%; driven by strong operating performance |
| Capacity Utilization | ~65% | Up from ~50%; management targeting ~75% by end FY27 |
| Exports Share | 69% of revenue | Domestic grew ~10% YoY; major growth from export markets |
| Industrial Chemicals Share | 89% of revenue | Primary growth segment; new chemistries contributing higher margins |
| Net Debt/EBITDA | 1.86x | Improved from 3.75x at Q4 FY26; driven by higher operating earnings and disciplined financial management |
| Working Capital Cycle | 143 days | Improved from 190 days; better inventory planning, receivables management and cash control |
| Capex (Q1 FY27) | ₹18.73 crores | Towards ongoing Pakhajan facility expansion |
| Credit Rating | A- (CRISIL & ICRA) | Upgraded from BBB during Q1 FY27 |
Geographic & Segment Commentary
Exports (69% of revenue): Exports remain the key growth pillar, with significant traction in US (post-tariff resolution), Europe, Middle East and other territories. Management is making new inroads into Asian and African markets, which were previously dominated by Asian majors; margins in new geographies are at par or slightly lower than existing markets. Management expects export share to settle in the 70-75% range, not higher.
Domestic: Domestic sales grew ~10% YoY during the quarter — growing but at a slower pace than exports. Domestic contribution declined on a percentage basis due to faster export growth, though absolute domestic revenue continues to increase.
Company-Specific & Strategic Commentary
Capacity Expansion: FY27 capex plan increased from ₹125 crores to ₹250 crores for two new production buildings at Pakhajan. Phase 1 (
₹100 crores) operational by Q1 FY28; Phase 2 (₹150 crores) by Q4 FY28. Management expects 2-2.5x revenue potential on capex; ~60-65% of new capacity already backed by customer commitments.R&D-Fueled Growth: R&D team of 50+ scientists; new products commercialized in last 12-24 months contributed ~30% of revenue growth. Employee-staffed subsidiaries in Europe (3 years) and US (2 years) gaining traction; US business recovering strongly post tariff resolution.
Long-Term Customer Agreements: Over 50% of revenue now from long-term supply contracts (quarterly/six-monthly/yearly pricing) versus 30-40% historically. Multiple marquee customer commitments secured with formula-based pricing; management cites NDA constraints on disclosing customers where no financial involvement exists.
FY28 Revenue Target Raised: Revenue target revised to >₹1,600 crores for FY28 (excludes revenue from new Phase 1/2 capex); driven by customer commitments and long-term supply contracts.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | 30-40% annual growth over next few years | Based on current market conditions, customer inquiries and commitments secured |
| FY28 Revenue | >₹1,600 crores | Excludes revenue from new ₹250 crores capex program; backed by committed customer offtake |
| EBITDA Margin | Sustain ~24% through FY27 | Supported by improved product mix, utilization ramp from 65% to 75%, formula-based pricing with long-term customers |
| Capacity Utilization | ~75% by FY27 end | Ramp-up driven by new customer approvals and committed offtake |
| New Facility Revenue | 2-2.5x of capex at peak | Phase 1 ( |
| Borrowings | ~₹100 crores during FY27 | To fund expanded capex program |
Risks & Constraints
| Risk | Context |
|---|---|
| Raw Material Supply Constraints | Management acknowledged genuine supply shortages on raw material side affecting inventory days; working capital improvement partially driven by insufficient raw material availability, not just efficiency gains |
| Logistics / Container Build Disruptions | Export shipments facing 3-4 week delays due to container booking shortages and reduced shipping availability; creates production scheduling and delivery timeline risks (delivery time at ~10 weeks) |
| Global Price Volatility & Margin Retention | While formula-based pricing with long-term customers provides stability, management cautioned that unforeseen market crises could impact margins; committed to maintaining current levels but not promising further expansion |
| EV Transition Risk for Lubricants | Analyst flagged ICE dependence of lubricants business; management assessed EV impact at 15-20 year horizon, not a near-term threat, but acknowledged product diversification strategy in response |
| Competitive / Chinese Dumping Pressure | Management downplayed risk given $12-15 billion addressable market and Company's modest $200-300 million revenue ambition; noted customers seeking alternate supply chains as a tailwind |
Q&A Highlights
Margin Sustainability & Drivers
Question: Can the 24% EBITDA margin be sustained given price hikes and operating leverage, and could normalization in supply chain or pricing pressure margins? (Meet Katrodiya)
Answer: Margins achieved through higher volumes, right product mix, and capacity utilization — not old stock gains. Customer commitments support confidence in maintaining margins. Volumes are expected to grow sequentially. (Parag Jhaveri)
Question: Historically management guided 17-20% margins; what fundamentally changed to support ~24%? (Parth Agarwal)
Answer: Three factors: (1) utilization improved from 50% to 65%, (2) customer offtake increased, (3) product mix changed. R&D support and process optimization delivered margin improvement. Even from 65% to 75% utilization, management expects further operating leverage benefits. (Parag Jhaveri)
Capex Expansion & New Products
- Question: What products will be manufactured at the two new Pakhajan buildings, and what is capacity and revenue potential? (Nishita Shanklesha)
- Answer: All industrial chemicals — a mix of existing products (capacity increase) and new molecules from R&D pipeline. Company stopped disclosing plant-level capacity. Phase 1 (
₹100 crores) operational Q1 FY28; Phase 2 (₹150 crores) by Q4 FY28. Construction, erection and stabilization takes minimum 15 months. Peak revenue potential of 2-2.5x capex. (Parag Jhaveri)
Customer Commitments & Growth Sustainability
- Question: Are we seeing green shoots from other OMC players for long-term contracts, and is this quarter's volume partly preemptive buying due to tariffs? (Pujan Shah)
- Answer: Company has commitments from multiple marquee customers on long-term supply arrangements beyond the disclosed OMC agreement. Non-disclosed agreements have no financial involvement and are under NDA, so names cannot be shared. Volume growth is backed by customer commitments, not preemptive buying. (Parag Jhaveri)
Pricing Mechanism
- Question: Did the company pass through the previously discussed 10-15% price hike, and will it sustain? Also, does EBITDA per kg or percentage remain constant? (Amar Maurya)
- Answer: Prices are formula-driven based on raw material costs with long-term suppliers/marquee customers — not market-driven. Quarterly and six-monthly pricing negotiations allow better positioning. EBITDA percentage remains constant, not per kg. Price increases flow through when raw material prices rise; when they fall, prices reduce. (Parag Jhaveri)
New Product Contributions & Utilization
- Question: What is the revenue contribution from products commercialized in the last 18-24 months, and what will be the contribution over the next 2-3 years? (Disha Chamriya)
- Answer: New product chemistry contributed ~30% of the revenue growth from ₹600 crores to ₹850 crores over the last two years. Going forward, all incremental growth will come from new chemistry. New products carry ~10-12% higher margins than legacy products. Company-level utilization is at 60-65%. Top customer contributes only ~7-8% of revenue, indicating no concentration risk. (Parag Jhaveri)
Export Growth & Market Dynamics
- Question: Who is the Company gaining share from, which export markets are driving growth, and is ICE/lubricant exposure a terminal risk? (Aman Thadani, Jainam Madrecha)
- Answer: Market share gains are coming from US (post-tariff recovery), Middle East, Europe, and new inroads into Asian and African markets previously dominated by Asian majors. Management cannot identify specific competitors being replaced. EV/lubricant transition is not seen as a threat within a 10-year horizon, as EV impact will materialize over 15-20 years. Domestic sales are growing ~10% YoY but faster export growth is shifting the mix. (Parag Jhaveri)
Supply Chain Challenges & Working Capital
- Question: Are there procurement/inventory risks given the war situation and macro uncertainty, especially since working capital has declined sharply? (Aman Thadani)
- Answer: Management acknowledged genuine supply issues on raw material procurement and export container booking delays (3-4 weeks). Delivery time has extended to ~10 weeks. Working capital improvement partly reflects raw material shortages, not purely efficiency gains. Team is working hard to ensure sufficient raw material inventory and fulfill customer commitments amid challenging logistics environment. (Parag Jhaveri)
New Capacity Utilization & Revenue Timing
- Question: The ₹1,600 crores FY28 guidance excludes the new capex; what revenue potential can we expect from Phase 1, and is 60-65% of the new capacity already booked? (Subhanu, Dakshesh Gupta)
- Answer: ¥1,600 crores guidance excludes the new capex program. Revenue from new capacity scales at 2-2.5x of capex. Phase 1 could contribute ~₹100 crores in FY28 at 50% utilization. ~65% of the new capacity is already backed by customer commitments, with the balance to be filled through market development. Real growth from new facilities expected from FY29. (Parag Jhaveri)
Key Takeaway
Yasho Industries delivered a record Q1 FY27 with revenue of ₹308 crores (+42% volume growth) and a sharp EBITDA margin expansion from 17% to 24.2%, driven by improved capacity utilization (~65%), a favorable product mix shift toward new higher-margin chemistries, and formula-based long-term contracts now covering over 50% of revenue. The Company raised its FY27 capex plan to ₹250 crores for two new production buildings at Pakhajan (Phase 1 by Q1 FY28, Phase 2 by Q4 FY28), with ~65% of capacity pre-booked by marquee customers, and revised its FY28 revenue target to ₹1,600+ crores. Credit rating upgrades to A- (CRISIL/ICRA), net debt/EBITDA improvement to 1.86x, and a 47-day working capital cycle reduction strengthen the balance sheet. Key watch points include raw material procurement and container logistics constraints, which temporarily aided working capital metrics but pose operational risks. Management is confident of sustaining ~24% EBITDA margins through FY27 while targeting 30-40% annual revenue growth, with material incremental contribution expected from new capacity in FY29 onward.